Government-Owned Inventions; Availability for Licensing, 10022-10023 [2017-02674]
Download as PDF
10022
Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications/
contract proposals, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Questions
in Cancer System Biology.
Date: March 2, 2017.
Time: 8:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
2E908, Rockville, MD 20850.
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Bethesda, MD 20892–9750,
240–276–6368, stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Tools for
Monitoring RNA.
Date: March 14, 2017.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
4W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W238, Bethesda, MD 20892–
9750, 240–276–6371, decluej@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Co-Clinical
Imaging.
Date: March 30, 2017.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Kenneth L. Bielat, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W244, Rockville, MD 20892–
9750, 240–276–6373, bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Collaborative Consortia for the Study of HIVAssociated Cancers (U54) RFA–CA–16–018.
Date: April 5–6, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
VerDate Sep<11>2014
18:11 Feb 08, 2017
Jkt 241001
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Rockville, MD 20892–9750,
240–276–6368, stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Center Support Grant.
Date: April 7, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Caterina Bianco, MD,
Ph.D., Scientific Review Officer, Research
Programs Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W110, Bethesda, MD 20892–9750,
240–276–6459, biancoc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 3, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02621 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
SUMMARY:
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Small Molecule Imaging of Fungi by
Positron Emission Tomography
Scanning
Description of Technology
This technology relates to the field of
radioactive, isotopically-labeled
calcofluor derivatives and uses of such
compounds to detect a broad spectrum
of filamentous fungi including
pathogenic species such as Aspergillus
and Mucorales, by diagnostic imaging
methods such as positron emission
tomography (PET) scanning.
Aspergillosis and other filamentous
fungal infections are increasingly
common fungal lung infection with high
mortality rates (over 50%) in immune
compromised patients, such as those
receiving chemotherapy, stem cell/organ
transplantation, or HIV patients. Oneyear survival of the infected patients
ranges from 59% (organ transplant
recipients) to as low as 25% (stem cell
transplant recipients). Delayed
diagnosis and therapy are likely to lead
to poor outcomes and death. This
disease is often first detected as nodules
on CT scans. A diagnosis is typically
made following invasive lung
bronchoscopy or biopsy. However, as
these patients are
immunocompromised, these invasive
procedures may themselves lead to
significant complications and
infections. Therefore, to enable timely
treatment and minimize complications,
there is a critical need for non-invasive
means to detect and diagnose fungal
infections.
The calcofluor derivatives disclosed
in the patent application may be
utilized as imaging agents specific for
fungal infections and could potentially
become a standard, non-invasive
procedure in the work-up of
immunocompromised patients with
lung infections.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications
• Diagnostics of Aspergillosis and
other filamentous fungal infections.
Competitive Advantages
• Non-invasive.
E:\FR\FM\09FEN1.SGM
09FEN1
Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices
• Low toxicity.
• Specific for Aspergillus.
10023
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Development Stage
National Institutes of Health
• In vivo data available (animal).
Inventors: Peter R. Williamson
(NIAID), Dale O. Kiesewetter (NIBIB),
John C. Panepinto (University of
Buffalo), and Jin Qiu (NIAID).
National Cancer Institute; Notice of
Closed Meetings
Dated: February 3, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
Publications
sradovich on DSK3GMQ082PROD with NOTICES
1. Palmer GE, et al., The diverse roles
of autophagy in medically important
fungi, Autophagy. 2008 Nov; 4(8):982–8.
[PMID 18927489]
2. Panepinto JC, et al., Deletion of the
Aspergillus fumigatus gene encoding
the Ras-related protein RhbA reduces
virulence in a model of invasive
pulmonary aspergillosis, Infect Immun.
2003 May; 71(5):2819–26. [PMID
12704156]
3. Desoubeaux D, et al., Diagnosis of
invasive pulmonary aspergillosis:
Updates and recommendations, Med
Mal Infect. 2014 Mar; 44(3):89–101.
[PMID 24548415]
Intellectual Property: HHS Reference
Nos. E–449–2013/0,1—U.S. Provisional
Application No. 61/894,754, filed
October 23, 2013; PCT Application No.
PCT/US2014/061917, filed October 23,
2014 (published as WO 2015/061540 on
April 30, 2015); European Application
No. 14800182.9, filed October 23, 2014
(pending); Australian Application No.
2014340035, filed October 23, 2014
(pending); Canadian Application No.
2927952, filed October 23, 2014; and
U.S. Application No. 15/030,554, filed
April 19, 2016 (pending).
Licensing Contact: Dr. David Yang,
240–627–3413; polung.yang@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize for development of this
invention. For collaboration
opportunities, please contact Dr. David
Yang, 240–627–3413; polung.yang@
nih.gov.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–02674 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:11 Feb 08, 2017
Jkt 241001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the Board of
Scientific Counselors for Basic Sciences,
National Cancer Institute and the Board
of Scientific Counselors for Clinical
Sciences and Epidemiology, National
Cancer Institute.
The meetings will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors for Clinical Sciences and
Epidemiology, National Cancer Institute.
Date: March 6, 2017.
Time: 8:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, 31
Center Drive, Building 31, C–Wing, 6th Floor,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Brian E. Wojcik, Ph.D.,
Senior Review Administrator, Institute
Review Office, Office of the Director,
National Cancer Institute, National Institutes
of Health, 9609 Medical Center Drive, Room
3W414, Bethesda, MD 20892, 240–276–5664,
wojcikb@mail.nih.gov.
Name of Committee: Board of Scientific
Counselors for Basic Sciences, National
Cancer Institute.
Date: March 7, 2017.
Time: 9:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, 31
Center Drive, Building 31, C–Wing, 6th Floor,
Conference Room 6, Bethesda, MD 20892.
Contact Person: Mehrdad Tondravi, Ph.D.,
Chief, Institute Review Office, Office of the
Director, National Cancer Institute, National
Institutes of Health, 9609 Medical Center
Drive, Room 3W–302, Bethesda, MD 20892,
240–276–5664, tondravim@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
PO 00000
Frm 00041
Fmt 4703
Sfmt 9990
[FR Doc. 2017–02615 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: March 6, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Kelly Y. Poe, Ph.D.,
Scientific Review Office, Scientific Review
Program, Division of Extramural Activities,
Room 3F40B, National Institutes of Health,
NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, (240) 669–5036,
poeky@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 3, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–02620 Filed 2–8–17; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\09FEN1.SGM
09FEN1
Agencies
[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Pages 10022-10023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02674]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Small Molecule Imaging of Fungi by Positron Emission Tomography
Scanning
Description of Technology
This technology relates to the field of radioactive, isotopically-
labeled calcofluor derivatives and uses of such compounds to detect a
broad spectrum of filamentous fungi including pathogenic species such
as Aspergillus and Mucorales, by diagnostic imaging methods such as
positron emission tomography (PET) scanning.
Aspergillosis and other filamentous fungal infections are
increasingly common fungal lung infection with high mortality rates
(over 50%) in immune compromised patients, such as those receiving
chemotherapy, stem cell/organ transplantation, or HIV patients. One-
year survival of the infected patients ranges from 59% (organ
transplant recipients) to as low as 25% (stem cell transplant
recipients). Delayed diagnosis and therapy are likely to lead to poor
outcomes and death. This disease is often first detected as nodules on
CT scans. A diagnosis is typically made following invasive lung
bronchoscopy or biopsy. However, as these patients are
immunocompromised, these invasive procedures may themselves lead to
significant complications and infections. Therefore, to enable timely
treatment and minimize complications, there is a critical need for non-
invasive means to detect and diagnose fungal infections.
The calcofluor derivatives disclosed in the patent application may
be utilized as imaging agents specific for fungal infections and could
potentially become a standard, non-invasive procedure in the work-up of
immunocompromised patients with lung infections.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
Diagnostics of Aspergillosis and other filamentous fungal
infections.
Competitive Advantages
Non-invasive.
[[Page 10023]]
Low toxicity.
Specific for Aspergillus.
Development Stage
In vivo data available (animal).
Inventors: Peter R. Williamson (NIAID), Dale O. Kiesewetter
(NIBIB), John C. Panepinto (University of Buffalo), and Jin Qiu
(NIAID).
Publications
1. Palmer GE, et al., The diverse roles of autophagy in medically
important fungi, Autophagy. 2008 Nov; 4(8):982-8. [PMID 18927489]
2. Panepinto JC, et al., Deletion of the Aspergillus fumigatus gene
encoding the Ras-related protein RhbA reduces virulence in a model of
invasive pulmonary aspergillosis, Infect Immun. 2003 May; 71(5):2819-
26. [PMID 12704156]
3. Desoubeaux D, et al., Diagnosis of invasive pulmonary
aspergillosis: Updates and recommendations, Med Mal Infect. 2014 Mar;
44(3):89-101. [PMID 24548415]
Intellectual Property: HHS Reference Nos. E-449-2013/0,1--U.S.
Provisional Application No. 61/894,754, filed October 23, 2013; PCT
Application No. PCT/US2014/061917, filed October 23, 2014 (published as
WO 2015/061540 on April 30, 2015); European Application No. 14800182.9,
filed October 23, 2014 (pending); Australian Application No.
2014340035, filed October 23, 2014 (pending); Canadian Application No.
2927952, filed October 23, 2014; and U.S. Application No. 15/030,554,
filed April 19, 2016 (pending).
Licensing Contact: Dr. David Yang, 240-627-3413;
polung.yang@nih.gov.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize for development of this invention.
For collaboration opportunities, please contact Dr. David Yang, 240-
627-3413; polung.yang@nih.gov.
Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-02674 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P